Genomics: doing Moore with less
17 February, 2003 by Graeme O'NeillGenomics is experiencing its own manifestation of computing technology's Moore's law of cost and efficiency, says Prof Richard Gibbs: the volume of sequence data is increasing by around 10-fold every year as sequencing costs continue to plummet.
DNA shuffling in the genetics game
13 February, 2003 by Graeme O'NeillDr Willem (Pim) Stemmer has spent the past decade demonstrating, in the most graphic manner possible, the value of biodiversity, and the existence of a massive genetic treasure trove in nature, far greater than the sum of its individual components.
Nobel headcount grows for Genetics Congress
13 February, 2003 by Graeme O'NeillThe Nobel winner count for July's International Congress of Genetics has risen to eight, with confirmation that Sir John Sulston will be joining fellow 2002 Medicine laureates Sir Sydney Brenner and Prof Robert Horvitz in Melbourne.
Revolution in genetics tipped as brave new world of RNA revealed
11 February, 2003 by Graeme O'NeillA new branch of genetics is being born. It might legitimately be called junk science, but Prof John Mattick has dubbed it 'Rnomics'... and it's the stuff of revolution.
New supercomputers for Queensland facility
30 January, 2003 by Pete YoungQuadrupled throughput capacity at the Queensland Parallel Supercomputer Foundation (QPSF) is part of an upsurge in high-performance computing resources becoming available to life science-oriented researchers.
Gene therapy shouldn't be abandoned: Australian researcher
15 January, 2003 by Graeme O'NeillThe US Food and Drug Administration this week suspended about 30 gene-therapy trials in the US after another 'boy in a bubble' patient in a French gene-therapy trial developed leukaemia. But Australian gene-therapy expert Assoc Prof Panos Ioannou said the setback did not mean gene therapy should be abandoned, or that it posed unacceptable risks.
CSIRO maths guru quits for private sector
20 December, 2002 by Pete YoungCSIRO is losing the services of one of the country's premier biostatisticians, Dr Mervyn Thomas, who is leaving to launch his own consultancy in the private sector.
New SA fund to help early-stage companies
13 December, 2002 by Melissa TrudingerA new biotech funding initiative in South Australia, the BioCatalyst Program Fund, will provide grants of up to $250,000 to start up and early stage companies to help them commercialise their ideas.
Genetic research joins centre of excellence roster
13 December, 2002 by Pete YoungGenetic research will occupy the focus of two of eight new centres of excellence which together will share almost $90 million in Federal funding over the next five years.
Gradipore touts US growth after gel range expansion
11 December, 2002 by Iain ScottSydney-based company Gradipore is predicting increased sales in its main US market after launching a new range of electrophoresis gels.
Data visualisation: See what you're doing?
11 December, 2002 by Pete YoungThe growing sophistication of data visualisation applications has been a boon for pharmaceutical and biotech researchers across the life and chemical sciences spectrum. Visualisation platforms help computational chemists to model molecules in drug discovery environments and genomic researchers to stitch useable information together from a confusing tangle of data held in different gene sequence databases.
Commercialisation: When institutes go to market
10 December, 2002 by David BinningAdvances in techniques for growing neurons, stem cell research, genetics, proteomics and massively improved capabilities in imaging are opening up previously undreamed-of avenues to treat sufferers of everything from epilepsy, stroke, chronic pain, multiple sclerosis, paralysis and psychosis.
Autogen promises free access to gene search tool
09 December, 2002 by Melissa TrudingerA bioinformatics tool developed by Melbourne company Autogen to search public domain gene databases for specific genes of interest will be made available to academic researchers for free.
Funding the festival
05 December, 2002 by Graeme O'NeillThe land of the red 'roo is a long hop from just about everywhere else in the world, so travel costs loomed large in Dr Phil Batterham's analysis of the cost of staging the world's largest genefest in Melbourne next year.
Genetic Technologies chief defends Myriad deal
03 December, 2002 by Melissa TrudingerGenetic Technologies' executive chairman Dr Mervyn Jacobson is surprised and disappointed by recent criticism of the deal he brokered with US genetic testing giant Myriad Genetics.
